• Mainz Biomed NV MYNZ.OQ, MYNZ.O is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending March 31 2024

• The Mainz Hessen-based company is expected to report a 10.0% decrease in revenue to $225 thousand from $250 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Mainz Biomed NV is for a loss of 25 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Mainz Biomed NV is $2.00​, above​ its last closing price of $0.22. ​​​

This summary was machine generated November 8 at 15:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)